Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling

Hui-Ping Lin1, Ching-Yu Lin, Chun-Chieh Liu

  • 1Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan. cpchuu@nhri.org.tw.

International Journal of Molecular Sciences
|March 8, 2013
PubMed

Insights

Caffeic acid phenethyl ester (CAPE), an antioxidant, shows promise for treating advanced prostate cancer by inhibiting the PI3K/Akt pathway, which is often dysregulated in recurrent tumors.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Prostate cancer is a leading global cancer, with metastatic disease often becoming castration-resistant despite androgen ablation therapy.
  • Recurrent prostate tumors frequently exhibit PTEN mutations, leading to aberrant PI3K/Akt signaling, a key driver of cancer progression.
  • Current treatments for metastatic hormone-refractory prostate cancer, including chemotherapy, offer limited survival benefits.

Purpose of the Study:

  • To review the potential of Caffeic acid phenethyl ester (CAPE) as a therapeutic agent for advanced prostate cancer.
  • To explore CAPE's mechanism of action, specifically its role in inhibiting the PI3K/Akt signaling pathway.
  • To highlight CAPE as a potential treatment targeting Akt signaling in recurrent prostate tumors.

Main Methods:

  • Literature review of studies on prostate cancer, androgen ablation therapy, and PI3K/Akt signaling.
  • Analysis of research on Caffeic acid phenethyl ester (CAPE), its properties, and its effects on cancer cells.
  • Examination of studies investigating CAPE's impact on Akt signaling and tumor growth in prostate cancer models.

Main Results:

  • The PI3K/Akt signaling pathway is frequently activated in advanced prostate cancer, particularly in castration-resistant tumors.
  • Caffeic acid phenethyl ester (CAPE), a natural antioxidant and NF-κB inhibitor, has demonstrated tumor growth suppression in prostate cancer cells.
  • CAPE treatment has been shown to inhibit Akt signaling in human prostate cancer cells.

Conclusions:

  • Inhibition of the PI3K/Akt pathway presents a viable therapeutic strategy for advanced prostate cancer.
  • Caffeic acid phenethyl ester (CAPE) exhibits potential as a novel treatment for advanced prostate cancer by targeting the Akt signaling pathway.
  • Further research into CAPE's efficacy and safety is warranted for its clinical application in prostate cancer treatment.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...